- 3 clinical studies -1 with an updated abstract on November 7th?

First - how big a market is this?:
http://www.cancer.gov/cancertopics/types...

Excerpt: "Definition of non-Hodgkin lymphoma: Any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin lymphoma. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either B-cells or T-cells. B-cell non-Hodgkin lymphomas include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell non-Hodgkin lymphomas include mycosis fungoides, anaplastic large cell lymphoma, and precursor T-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas. Prognosis and treatment depend on the stage and type of disease. Also called NHL.

Estimated new cases and deaths from non-Hodgkin lymphoma in the United States in 2009:
New cases: 65,980
Deaths: 19,500"

Sanofi Aventis's 3 current clinical trials:

http://clinicaltrials.gov/ct2/results?te...
&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=

I think this is the one we will hear about on the 7th - is should have concluded in June 2009:
http://clinicaltrials.gov/ct2/show/NCT00...

WILL THERE BE ANY TUMOR RESPONSE REPORTED?:

"Primary Outcome Measures:
Incidence of Dose Limiting Toxicity(ies) at each tested dose level [ Time Frame: Study period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
Tumor response (complete response, partial response, stable disease) according to Cheson criteria and duration of response [ Time Frame: Study period ] [ Designated as safety issue: No ]
Incidence of Adverse Events [ Time Frame: Study period ] [ Designated as safety issue: Yes ]"

A SECOND CLINICAL STUDY TO BE CONCLUDED IN OCTOBER 2009:

"Estimated Enrollment: 40
Study Start Date: October 2007
Estimated Primary Completion Date:October 2009
(Final data collection date for primary outcome measure)"

ON JUNE 22, 2009 THIS STUDY WENT FROM 40 PATIENTS TO 50 ACCORDING TO THE HISTORY OF CHANGES. HOW SOON BEFORE WE HEAR ABOUT THIS STUDY? IN DECEMBER?

A THIRD CLINICAL STUDY TO CONCLUDE IN JANUARY 2010:

"Estimated Enrollment: 40
Study Start Date: October 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)"

NEXT WEEKEND'S REPORT WILL GIVE US A VIEW TO THE LIKELIHOOD OF SAR3419 PROGRESSING TO FUTURE DEVELOPMENT AS A DRUG, IMO